Pharmaceutical hofori Lilly, kambani yekuAmerica, uye Novo Nordisk, kambani yeDanish, vakatevedzana vazivisa data rekutengesa rezvigadzirwa zvavo zvikuru muna 2020: Dulaglutide yave TOP1 GLP-1 mushonga, nekutengesa kwe5.07Bn muna 2020, gore- pa-gore kuwedzera kwe22.8%;liraglutide Kutanga kupinda panguva yekudzika, kutengesa muna 2020 kwakadzikira kubva pamadhora mazana mana nemakumi mapfumbamwe nemakumi mapfumbamwe kusvika pamadhora mazana matatu nemakumi mapfumbamwe nemashanu, kuderera kwegore negore kwe5.1%;semaglutide yakakura nekukurumidza, nekutengesa kunosvika $3.72Bn muna 2020, kuwedzera kwegore-pagore kwe119.9%.
Lilly's dulaglutide (zita rekutengesa Trulicity®) yakavambwa muna 2014 uye ikava mushonga weblockbuster nekutengesa madhora 5.07Bn mumakore matanhatu chete, ndokuva shasha yekutengesa yeGLP-1 mishonga.Novo Nordisk's single product yakasara kumashure kweLilly.Yayo liraglutide (zita rekutengesa Victoza® uye Saxenda®), iyo yakavambwa muna 2009, yaimbova shasha yekutengesa yeGLP-1 mishonga, uye kutengesa kwayo kwepamusoro muna 2017 kwakasvika madhora 4.37Bn, kunyangwe paine zviratidzo zviviri zvechirwere cheshuga chechipiri uye kufutisa. , iyo data ye2020 inoratidza kuti musika wemushonga uyu wapinda munguva yekuderera.Iyo imwechete Novo Nordisk's semaglutide (mazita ekutengeserana Ozempic® uye Rybelsus®) yakakura nekukurumidza uye yakakura kuita mumwe mushonga we blockbuster nekutengesa kwe $ 3.72Bn mumakore matatu.Mushonga une maitiro maviri emushonga wejekiseni uye kugadzirira nemuromo.
Kubva pakuona kwenzvimbo, United States ndiyo inonyanya kutengesa nyika yeliraglutide, inoverengera ingangoita 60% muna 2020, kuderera kwegore-pagore kwe11.02%;ndiko zvakare kudzikira kwehupfumi muUnited States kwakonzera kudzikira kwemusika wepasi rose weliraglutide.Iyo EMEA (Europe, Middle East, Africa) nharaunda yakakura zvishoma nezvishoma, ine CAGR ye1.6% chete mumakore mashanu apfuura;China ndiyo musika uri kukurumidza kukurumidza, nekutengesa kwe $182.50Mn muna 2020, ine huwandu hwekukura kwegore hwe42.39%.Sezvo semaglutide yave pamusika munguva pfupi, misika yese iri padanho rekukura nekukurumidza.IUnited States ichiri misika huru, inoverengera 80.04% yekutengesa muna 2020, gore negore kuwedzera kwe106.08%;EMEA ine chete 13.64% share asi gore-pa-gore kukura mwero we249.65%%.Semaglutide yakavambwa muChina muna 2020 nekutengesa kwemadhora 1.61Mn.Mufananidzo 3 unoratidza mamiriro edunhu e dulaglutide.Semusika mukuru, United States ine kutengesa kwakakwira semadhora 3.836Bn, inoverengera 75.69%, ine huwandu hwekukura kwegore hwe79.18%.
Iwo epakati patents e liraglutide (Victoza® neSaxenda®) apera muChina uye ave kuda kupera muUS, Japan neGermany.Hondo yaTeva patent neNovo Nordisk yakagadziriswa, uye Teva's generic version ichavepo muna 2023. Mylan akaisawo ANDA application kuFDA yeliraglutide ine PIV claim.Nekupera kwenguva zvishoma nezvishoma kwepatents uye kutyisidzirwa kwevagadziri vemishonga yemazuva ese, mushonga unopinda zvishoma nezvishoma munguva yekuderera.Iyo US komputa patent yeTrulicity® haizoperi kusvika 2027, nepo macompound patents dzenyika huru dzeEurope neJapan hazvizopere kusvika 2029, uye iyo core patent dziviriro yakareba kupfuura iyo liraglutide.Iwo epakati patents e semaglutide (Ozempic® neRybelsus®) achapera muna 2032 munguva pfupi yapfuura, uye pachine nzvimbo huru yekukura kwemusika, asi nguva yayo yekupera muChina i2026.
Nguva yekutumira: Jul-25-2022